Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT-Reference-Cited by-同舟云学术

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT

Published:2017-01 Issue:1 Volume:31 Page:64-78
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Paul Juliane,Soujon Maurice,Wengner Antje M.,Zitzmann-Kolbe Sabine,Sturz Andrea,Haike Katja,Keng Magdalene Koh Hui,Tan Sze Huey,Lange Martin,Tan Soo Yong,Mumberg Dominik,Lim Soon Thye,Ziegelbauer Karl,Liu Ningshu

Funder

Bayer AG

Aurexel Life Sciences Ltd.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference38 articles.

1. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J. Clin. Oncol.,2013

2. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy;Buggy;Int. Rev. Immunol.,2012

3. The potent PI3K-δ,γ inhibitor, IPI-145, exhibits differential activity in diffuse large B-cell lymphoma (DLBCL) cell lines;Campbell;Blood,2013

4. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors;Ceribelli;Proc. Natl. Acad. Sci. USA,2014

5. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies;Chou;Pharmacol. Rev.,2006

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer;Journal of Translational Medicine;2024-07-09

2. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma;Leukemia;2024-06-21

3. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma;Signal Transduction and Targeted Therapy;2024-04-17

4. NF-κB in biology and targeted therapy: new insights and translational implications;Signal Transduction and Targeted Therapy;2024-03-04

5. Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?;Expert Opinion on Therapeutic Targets;2024-03-03